(C) Reuters. Zomedica vs. Phibro Animal Health: Which Pet Stock is a Better Buy?
If there is one industry that seems to be recession proof, it’s pet products. Pet owners will do anything, and spend anything on their furry best friends. That’s why pet stocks offer long-term potential. Zomedica (ZOM) and Phibro Animal Health (NASDAQ:PAHC) are two animal health stocks worth considering, but which is a better buy? Read more to find out.Choosing where to invest your money is becoming a little more difficult now that the economy is gradually returning to normal. Some of the pandemic trends will continue while others fizzle out.
Several sectors have the potential to pop as we transition to a post-coronavirus world. There could be an extended return to value stocks. Maybe gas and oil stocks will jump as travel booms. There are plenty of uncertainties ahead, yet there are no arguing people will continue spending money on animal health.
Pet stocks are clearly a solid play moving forward. However, selecting the best pet stock for your portfolio will prove challenging. Let’s take a look at two top pet stocks in Zomedica (ZOM) and Phibro Animal Health (PAHC).
Zomedica vs. Phibro Animal Health: Which Pet Stock is a Better Buy?
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.